The startup Ailin, the first platform that offers a convenient, efficient and secure diagnostic support solution to know and monitor people’s health status, has announced the successful closing of its first official financing round, reaching a significant figure of 1.5 million euros. This round has been possible thanks to the backing of private investors and public support from CDTI through the Neotec program.
Since its inception, Ailin has stood out for its visionary approach, initially raising FFF funds to start its journey. Now, despite challenging market circumstances, the startup exceeds its initial fundraising expectations.
The round has been underwritten by a family office with strong ties in the healthcare sector, positioning themselves as strategic investors. Business Angels with experience in private equity, strategic consulting and serial entrepreneurs have also participated, along with two impact funds also related to the healthcare field, including Decelera Ventures.
Marcos Martín, CEO of Decelera Ventures, expressed his confidence in Ailin’s project: “We invested in Ailin because of its ability to address, in an innovative and differential way, one of the great challenges of the healthcare sector. Isabel’s dedication and vision, backed by an experienced team in the sector, strengthen our confidence in the project, which marks the path towards a healthier and more accessible future”.
The investment will drive Ailin’s technological development, incorporating Artificial Intelligence algorithms to provide more accurate health diagnostics. In addition, a significant portion of the funds will go towards hiring talent to strengthen the team.
“This investment round will allow us to advance the development of a new market category that brings diagnostic testing closer to home and seeks to drive a more prevention-focused healthcare model,” says Isabel Caruana, CEO and founder of Ailin.
By 2024, Ailin aims to consolidate strategic alliances, expanding its collaboration with institutions such as the Clínica Universidad de Navarra and seeking partnerships with leading health insurers and pharmaceutical laboratories, among others.
At the product level, the company plans to expand its catalog of kits, including a new line for intolerances (fructose, lactose and SIBO). These tests, which affect one in four people, will allow patients to perform them comfortably from home, with results that will include a health plan designed by specialists. Ailin will continue to favor biomarker research and the incorporation of artificial intelligence models to detect a greater number of diseases, strengthening its commitment to innovation in the healthcare sector.
The revolution in home diagnostics
Ailin is the leading platform in diagnostic support solutions, positioning itself as a pioneer by offering people a convenient, efficient and safe way to know and monitor their health status from the comfort of their homes, at any time they wish.
Ailin’s innovative approach is based on two fundamental pillars:
- Self-testing kits allow patients to access laboratory tests from anywhere, eliminating the need to travel to a medical center. Simultaneously, the Results Interpretation Software makes it easy for physicians to custom interpret results in a fraction of the usual time, allowing patients to understand their results and take action to achieve optimal health.
- Notably, the startup has grown by x7 in 2023, with an average monthly growth of 60% in the last quarter. Growth that lies in solving real needs of its users, who show a high degree of satisfaction with the solution they propose – its Net Promoter Score (NPS) is 72%, much higher than the 49% of the main English competitor. By 2024, it expects to multiply its turnover growth tenfold and reach more than 10,000 patients.
- With these achievements and technological advances, Ailin is consolidating its position as the leading option for those seeking a revolutionary and efficient approach to personalized and accessible health diagnostics.